Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Breast Cancer Retrieve available abstracts of 131 articles: HTML format Text format

Single Articles

July 2018
1. OKUMATSU K, Tsujimoto T, Wakaba K, Seki A, et al
   Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients.
   Breast Cancer. 2018 Jul 10. pii: 10.1007/s12282-018-0889.
   PubMed     Text format     Abstract available
   
   
   
2. MA D, Chen C, Wu J, Wang H, et al
   Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
   Breast Cancer. 2018 Jul 5. pii: 10.1007/s12282-018-0891.
   PubMed     Text format     Abstract available
   
   
   
3. TOKUNAGA E, Fujita A, Takizawa K, Baba K, et al
   CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
   Breast Cancer. 2018 Jul 3. pii: 10.1007/s12282-018-0888.
   PubMed     Text format     Abstract available
   
   
   June 2018
4. PENG X, Yan B, Shen Y
   MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1.
   Breast Cancer. 2018 Jun 27. pii: 10.1007/s12282-018-0881.
   PubMed     Text format     Abstract available
   
   
   
5. LIU L, Yin B, Yi Z, Liu X, et al
   Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs.
   Breast Cancer. 2018 Jun 14. pii: 10.1007/s12282-018-0880.
   PubMed     Text format     Abstract available
   
   
   
6. TAKABATAKE D, Kajiwara Y, Ohtani S, Itano Y, et al
   The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.
   Breast Cancer. 2018 Jun 11. pii: 10.1007/s12282-018-0877.
   PubMed     Text format     Abstract available
   
   
   
7. TOYAMA T, Yoshimura A, Hayashi T, Kobayashi N, et al
   A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
   Breast Cancer. 2018 Jun 8. pii: 10.1007/s12282-018-0879.
   PubMed     Text format     Abstract available
   
   
   May 2018
8. LOUHICHI T, Ziadi S, Saad H, Dhiab MB, et al
   Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
   Breast Cancer. 2018 May 29. pii: 10.1007/s12282-018-0875.
   PubMed     Text format     Abstract available
   
   
   
9. SAJI S
   The long and winding road for overcoming resistance to hormone therapy in breast cancer.
   Breast Cancer. 2018 May 28. pii: 10.1007/s12282-018-0876.
   PubMed     Text format    
   
   
   
10. GAO L, Li SC
    Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.
    Breast Cancer. 2018 May 25. pii: 10.1007/s12282-018-0872.
    PubMed     Text format     Abstract available
    
    
    
11. WEN L, Liu L, Wen L, Yu T, et al
    Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0873.
    PubMed     Text format     Abstract available
    
    
    
12. OSTAPCHUK YO, Perfilyeva YV, Kustova EA, Urazalieva NT, et al
    Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0874.
    PubMed     Text format     Abstract available
    
    
    
13. LEE SB, Sohn G, Kim J, Chung IY, et al
    Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study.
    Breast Cancer. 2018 May 21. pii: 10.1007/s12282-018-0869.
    PubMed     Text format     Abstract available
    
    
    
14. TAKADA M, Takeuchi M, Suzuki E, Sato F, et al
    Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence.
    Breast Cancer. 2018 May 9. pii: 10.1007/s12282-018-0868.
    PubMed     Text format     Abstract available
    
    
    
15. JAMAN MS, Sayeed MA
    Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives.
    Breast Cancer. 2018 May 3. pii: 10.1007/s12282-018-0866.
    PubMed     Text format     Abstract available
    
    
    April 2018
16. KWAPISZ D
    Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Breast Cancer. 2018 Apr 26. pii: 10.1007/s12282-018-0864.
    PubMed     Text format     Abstract available
    
    
    
17. SAKAI H, Tsurutani J, Iwasa T, Komoike Y, et al
    HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
    Breast Cancer. 2018 Apr 26. pii: 10.1007/s12282-018-0861.
    PubMed     Text format     Abstract available
    
    
    
18. WANG NN, Yang ZJ, Wang X, Chen LX, et al
    A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective analysis and nomogram development.
    Breast Cancer. 2018 Apr 25. pii: 10.1007/s12282-018-0863.
    PubMed     Text format     Abstract available
    
    
    
19. AOYAGI T, Takabe K, Tamanuki T, Matsubara H, et al
    Pseudocirrhosis after chemotherapy in breast cancer, case reports.
    Breast Cancer. 2018 Apr 25. pii: 10.1007/s12282-018-0865.
    PubMed     Text format     Abstract available
    
    
    
20. OHASHI R, Nagao M, Nakamura I, Okamoto T, et al
    Improvement in diagnostic performance of breast cancer: comparison between conventional digital mammography alone and conventional mammography plus digital breast tomosynthesis.
    Breast Cancer. 2018 Apr 12. pii: 10.1007/s12282-018-0859.
    PubMed     Text format     Abstract available
    
    
    
21. NAZARI SS, Mukherjee P
    An overview of mammographic density and its association with breast cancer.
    Breast Cancer. 2018 Apr 12. pii: 10.1007/s12282-018-0857.
    PubMed     Text format     Abstract available
    
    
    
22. LI Q, Gao H, Zhou S, Liao Y, et al
    LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-beta1 and downregulating PHGDH.
    Breast Cancer. 2018 Apr 6. pii: 10.1007/s12282-018-0858.
    PubMed     Text format     Abstract available
    
    
    
23. IWASE M, Sawaki M, Hattori M, Yoshimura A, et al
    Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery.
    Breast Cancer. 2018 Apr 4. pii: 10.1007/s12282-018-0856.
    PubMed     Text format     Abstract available
    
    
    March 2018
24. SASADA S, Shien T, Iwata H
    Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey.
    Breast Cancer. 2018 Mar 23. pii: 10.1007/s12282-018-0855.
    PubMed     Text format    
    
    
    
25. WAKABAYASHI H, Hamaguchi T, Nagao N, Kato S, et al
    Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.
    Breast Cancer. 2018 Mar 19. pii: 10.1007/s12282-018-0853.
    PubMed     Text format     Abstract available
    
    
    
26. ZHANG JM, Wei K, Jiang M
    OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer.
    Breast Cancer. 2018 Mar 13. pii: 10.1007/s12282-018-0844.
    PubMed     Text format     Abstract available
    
    
    
27. YOSHIMURA A, Okumura S, Sawaki M, Hattori M, et al
    Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    Breast Cancer. 2018 Mar 8. pii: 10.1007/s12282-018-0850.
    PubMed     Text format     Abstract available
    
    
    
28. KA WH, Cho SK, Chun BN, Byun SY, et al
    The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
    Breast Cancer. 2018 Mar 7. pii: 10.1007/s12282-018-0849.
    PubMed     Text format     Abstract available
    
    
    February 2018
29. RAMOS-ESQUIVEL A, Hernandez-Steller H, Savard MF, Landaverde DU, et al
    Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Breast Cancer. 2018 Feb 22. pii: 10.1007/s12282-018-0848.
    PubMed     Text format     Abstract available
    
    
    
30. NOGUCHI S, Ellis MJ, Robertson JFR, Thirlwell J, et al
    Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
    Breast Cancer. 2018 Feb 15. pii: 10.1007/s12282-018-0838.
    PubMed     Text format     Abstract available
    
    
    
31. MASUDA N, Toi M, Yamamoto N, Iwata H, et al
    Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicent
    Breast Cancer. 2018 Feb 14. pii: 10.1007/s12282-018-0839.
    PubMed     Text format     Abstract available
    
    
    
32. CHEN W, Lv X, Xu X, Gao X, et al
    Meta-analysis for psychological impact of breast reconstruction in patients with breast cancer.
    Breast Cancer. 2018 Feb 13. pii: 10.1007/s12282-018-0846.
    PubMed     Text format     Abstract available
    
    
    
33. OHTANI S, Nakayama T, Yoshinami T, Watanabe KI, et al
    Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
    Breast Cancer. 2018 Feb 12. pii: 10.1007/s12282-018-0843.
    PubMed     Text format     Abstract available
    
    
    
34. SURYAVANSHI M, Mehta A, Jaipuria J, Kumar D, et al
    Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients.
    Breast Cancer. 2018 Feb 9. pii: 10.1007/s12282-018-0840.
    PubMed     Text format     Abstract available
    
    
    
35. ZOU L, Liu FH, Shen PP, Hu Y, et al
    The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study.
    Breast Cancer. 2018 Feb 3. pii: 10.1007/s12282-018-0830.
    PubMed     Text format     Abstract available
    
    
    
36. IWATA H
    Clinical development of CDK4/6 inhibitor for breast cancer.
    Breast Cancer. 2018 Feb 1. pii: 10.1007/s12282-017-0827.
    PubMed     Text format     Abstract available
    
    
    January 2018
37. WANG Y, Wang J, Long F, Wang N, et al
    Correlation of FANCM expression with clinical factors in luminal B breast cancer.
    Breast Cancer. 2018 Jan 31. pii: 10.1007/s12282-018-0841.
    PubMed     Text format     Abstract available
    
    
    
38. KHAN RT, Siddique A, Shahid N, Khokher S, et al
    Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan.
    Breast Cancer. 2018 Jan 24. pii: 10.1007/s12282-018-0837.
    PubMed     Text format     Abstract available
    
    
    
39. NGUYEN-THU H, Hanaoka H, Nakajima T, Yamaguchi A, et al
    Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and (18)F-FDG-PET.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0834.
    PubMed     Text format     Abstract available
    
    
    
40. OZAKI Y, Tanabe Y, Tamura N, Ogura T, et al
    Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0836.
    PubMed     Text format     Abstract available
    
    
    
41. YANG ZJ, Yu Y, Chi JR, Guan M, et al
    The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual.
    Breast Cancer. 2018 Jan 20. pii: 10.1007/s12282-018-0833.
    PubMed     Text format     Abstract available
    
    
    
42. HABYARIMANA T, Attaleb M, Mazarati JB, Bakri Y, et al
    Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients.
    Breast Cancer. 2018 Jan 19. pii: 10.1007/s12282-018-0831.
    PubMed     Text format     Abstract available
    
    
    
43. INARI H, Shimizu S, Suganuma N, Yoshida T, et al
    Correction to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women.
    Breast Cancer. 2018 Jan 10. pii: 10.1007/s12282-018-0832.
    PubMed     Text format     Abstract available
    
    
    
44. PIVOT X, Im SA, Guo M, Marme F, et al
    Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
    Breast Cancer. 2018 Jan 4. pii: 10.1007/s12282-017-0826.
    PubMed     Text format     Abstract available
    
    
    December 2017
45. PIERRISNARD C, Baciuchka M, Mancini J, Rathelot P, et al
    Body image and psychological distress in women with breast cancer: a French online survey on patients' perceptions and expectations.
    Breast Cancer. 2017 Dec 29. pii: 10.1007/s12282-017-0828.
    PubMed     Text format     Abstract available
    
    
    
46. ATTALLAH AM, El-Far M, Abdelrazek MA, Omran MM, et al
    HCV nonstructural protein 4 is associated with aggressiveness features of breast cancer.
    Breast Cancer. 2017 Dec 28. pii: 10.1007/s12282-017-0829.
    PubMed     Text format     Abstract available
    
    
    
47. SHIMOI T, Yoshida M, Kitamura Y, Yoshino T, et al
    TERT promoter hotspot mutations in breast cancer.
    Breast Cancer. 2017 Dec 8. pii: 10.1007/s12282-017-0825.
    PubMed     Text format     Abstract available
    
    
    
48. TSUDA B, Miyamoto A, Yokoyama K, Ogiya R, et al
    B-cell populations are expanded in breast cancer patients compared with healthy controls.
    Breast Cancer. 2017 Dec 4. pii: 10.1007/s12282-017-0824.
    PubMed     Text format     Abstract available
    
    
    
49. DORFEL S, Steffens CC, Meyer D, Tesch H, et al
    Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
    Breast Cancer. 2017 Dec 4. pii: 10.1007/s12282-017-0823.
    PubMed     Text format     Abstract available
    
    
    
50. HE J, Chen Y, Cai L, Li Z, et al
    UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer.
    Breast Cancer. 2017 Dec 1. pii: 10.1007/s12282-017-0820.
    PubMed     Text format     Abstract available
    
    
    November 2017
51. INOUE H, Horii R, Ito Y, Iwase T, et al
    Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Breast Cancer. 2017 Nov 28. pii: 10.1007/s12282-017-0822.
    PubMed     Text format     Abstract available
    
    
    
52. ZHANG ZL, Jiang QC, Wang SR
    Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Breast Cancer. 2017 Nov 27. pii: 10.1007/s12282-017-0821.
    PubMed     Text format     Abstract available
    
    
    
53. ZHAO Q, Song W, He DY, Li Y, et al
    Identification of key gene modules and pathways of human breast cancer by co-expression analysis.
    Breast Cancer. 2017 Nov 23. pii: 10.1007/s12282-017-0817.
    PubMed     Text format     Abstract available
    
    
    
54. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Nov 20. doi: 10.1007/s12282-017-0815.
    PubMed     Text format     Abstract available
    
    
    
55. KASSEM L, Shohdy KS, Lasheen S, Abdel-Rahman O, et al
    Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Breast Cancer. 2017 Nov 16. doi: 10.1007/s12282-017-0818.
    PubMed     Text format     Abstract available
    
    
    
56. WANG R, Li J, Zhao Y, Li Y, et al
    Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
    Breast Cancer. 2017 Nov 14. doi: 10.1007/s12282-017-0816.
    PubMed     Text format     Abstract available
    
    
    
57. ADHAMI M, Haghdoost AA, Sadeghi B, Malekpour Afshar R, et al
    Candidate miRNAs in human breast cancer biomarkers: a systematic review.
    Breast Cancer. 2017 Nov 3. doi: 10.1007/s12282-017-0814.
    PubMed     Text format     Abstract available
    
    
    
58. SHIGEMATSU H, Ozaki S, Yasui D, Zaitsu J, et al
    Comparison of CK-IHC assay on serial frozen sections, the OSNA assay, and in combination for intraoperative evaluation of SLN metastases in breast cancer.
    Breast Cancer. 2017 Nov 1. doi: 10.1007/s12282-017-0811.
    PubMed     Text format     Abstract available
    
    
    
59. HARAO M, Ando J, Kamata H, Hoshi N, et al
    Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
    Breast Cancer. 2017 Nov 1. doi: 10.1007/s12282-017-0813.
    PubMed     Text format     Abstract available
    
    
    October 2017
60. ARAKI K, Miyoshi Y
    Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer. 2017 Oct 31. doi: 10.1007/s12282-017-0812.
    PubMed     Text format     Abstract available
    
    
    
61. KHPAL M, Miller JRC, Petrovic Z, Hassanally D, et al
    Local anesthetic delivery via surgical drain provides improved pain control versus direct skin infiltration following axillary node dissection for breast cancer.
    Breast Cancer. 2017 Oct 26. doi: 10.1007/s12282-017-0810.
    PubMed     Text format     Abstract available
    
    
    
62. REGEV-AVRAHAM Z, Baron-Epel O, Hammond SK, Keinan-Boker L, et al
    Passive smoking, NAT2 polymorphism, and breast cancer risk in Israeli Arab women: a case-control study.
    Breast Cancer. 2017 Oct 26. doi: 10.1007/s12282-017-0809.
    PubMed     Text format     Abstract available
    
    
    
63. OGITA M, Nagura N, Kawamori J, In R, et al
    Risk factors for complications among breast cancer patients treated with post-mastectomy radiotherapy and immediate tissue-expander/permanent implant reconstruction: a retrospective cohort study.
    Breast Cancer. 2017 Oct 19. doi: 10.1007/s12282-017-0808.
    PubMed     Text format     Abstract available
    
    
    
64. TOYODA Y, Tabuchi T, Nakayama T, Hojo S, et al
    Trends in the clinical stage distribution of breast cancer in Osaka, Japan.
    Breast Cancer. 2017 Oct 12. doi: 10.1007/s12282-017-0807.
    PubMed     Text format     Abstract available
    
    
    September 2017
65. ALTUNDAG K
    Questions about lower inner zone tumors in early-stage breast cancer.
    Breast Cancer. 2017 Sep 14. doi: 10.1007/s12282-017-0801.
    PubMed     Text format    
    
    
    August 2017
66. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Aug 31. doi: 10.1007/s12282-017-0798.
    PubMed     Text format     Abstract available
    
    
    
67. YAMAGUCHI T, Mukai H, Akiyama F, Arihiro K, et al
    Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer. 2017 Aug 30. doi: 10.1007/s12282-017-0799.
    PubMed     Text format     Abstract available
    
    
    
68. YANG J, Tang S, Zhou Y, Qiu J, et al
    Prognostic implication of the primary tumor location in early-stage breast cancer: focus on lower inner zone.
    Breast Cancer. 2017 Aug 18. doi: 10.1007/s12282-017-0797.
    PubMed     Text format     Abstract available
    
    
    July 2017
69. YU Z, Guo X, Jiang Y, Teng L, et al
    Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
    Breast Cancer. 2017 Jul 28. doi: 10.1007/s12282-017-0794.
    PubMed     Text format     Abstract available
    
    
    
70. NAKAMURA R, Yamamoto N, Miyaki T, Itami M, et al
    Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Breast Cancer. 2017 Jul 22. doi: 10.1007/s12282-017-0795.
    PubMed     Text format     Abstract available
    
    
    
71. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Erratum to: Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jul 7. doi: 10.1007/s12282-017-0792.
    PubMed     Text format    
    
    
    June 2017
72. NAKAI K, Xia W, Liao HW, Saito M, et al
    The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Breast Cancer. 2017 Jun 22. doi: 10.1007/s12282-017-0790.
    PubMed     Text format     Abstract available
    
    
    
73. SEKIGUCHI K
    Controversies in the role of postmastectomy radiotherapy in breast cancer patients with one to three positive axillary nodes and safety of integrating radiotherapy and breast reconstruction.
    Breast Cancer. 2017 Jun 14. doi: 10.1007/s12282-017-0788.
    PubMed     Text format    
    
    
    
74. YU X, Zhou S, Wang J, Zhang Q, et al
    Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies.
    Breast Cancer. 2017 Jun 10. doi: 10.1007/s12282-017-0789.
    PubMed     Text format     Abstract available
    
    
    
75. TADA K, Nishioka K, Kikuchi Y, Niwa T, et al
    Post-mastectomy radiation therapy in breast cancer with 1-3 involved lymph nodes: the Pros.
    Breast Cancer. 2017 Jun 5. doi: 10.1007/s12282-017-0787.
    PubMed     Text format     Abstract available
    
    
    May 2017
76. MIZOTA Y, Ohashi Y, Iwase T, Iwata H, et al
    Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan.
    Breast Cancer. 2017 May 25. doi: 10.1007/s12282-017-0784.
    PubMed     Text format     Abstract available
    
    
    
77. MATSUDA N, Kida K, Ohde S, Suzuki K, et al
    Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
    Breast Cancer. 2017 May 23. doi: 10.1007/s12282-017-0782.
    PubMed     Text format     Abstract available
    
    
    
78. TOMIOKA N, Azuma M, Ikarashi M, Yamamoto M, et al
    The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Breast Cancer. 2017 May 9. doi: 10.1007/s12282-017-0781.
    PubMed     Text format     Abstract available
    
    
    April 2017
79. LEUTERITZ K, Weissflog G, Barthel Y, Brahler E, et al
    Therapeutic alliance and treatment outcome in psychodynamic psychotherapy of depressed breast cancer patients: the same old story or different from other populations?
    Breast Cancer. 2017 Apr 28. doi: 10.1007/s12282-017-0777.
    PubMed     Text format     Abstract available
    
    
    
80. YAMAMOTO S, Maeda N, Nagashima Y, Kubo H, et al
    A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Breast Cancer. 2017 Apr 24. doi: 10.1007/s12282-017-0779.
    PubMed     Text format     Abstract available
    
    
    
81. KITAYAMA H, Kondo T, Sugiyama J, Kurimoto K, et al
    High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Breast Cancer. 2017 Apr 22. doi: 10.1007/s12282-017-0778.
    PubMed     Text format     Abstract available
    
    
    
82. GHEYBI MK, Farrokhi S, Ravanbod MR, Ostovar A, et al
    The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients.
    Breast Cancer. 2017 Apr 20. doi: 10.1007/s12282-017-0775.
    PubMed     Text format     Abstract available
    
    
    
83. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Breast Cancer. 2017 Apr 19. doi: 10.1007/s12282-017-0774.
    PubMed     Text format     Abstract available
    
    
    
84. HANAMURA T, Hayashi SI
    Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Breast Cancer. 2017 Apr 7. doi: 10.1007/s12282-017-0772.
    PubMed     Text format     Abstract available
    
    
    
85. MALEK-HOSSEINI Z, Jelodar S, Talei A, Ghaderi A, et al
    Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size.
    Breast Cancer. 2017 Apr 5. doi: 10.1007/s12282-017-0773.
    PubMed     Text format     Abstract available
    
    
    
86. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2017 Apr 4. doi: 10.1007/s12282-017-0771.
    PubMed     Text format    
    
    
    March 2017
87. LIN WZ, Xu QN, Wang HB, Li XY, et al
    Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
    Breast Cancer. 2017 Mar 21. doi: 10.1007/s12282-017-0770.
    PubMed     Text format     Abstract available
    
    
    
88. ALTUNDAG K
    Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
    Breast Cancer. 2017 Mar 8. doi: 10.1007/s12282-017-0767.
    PubMed     Text format    
    
    
    
89. GALLI G, Tessari A, Di Cosimo S
    Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history.
    Breast Cancer. 2017 Mar 6. doi: 10.1007/s12282-017-0766.
    PubMed     Text format    
    
    
    February 2017
90. KOGA C, Akiyoshi S, Ishida M, Nakamura Y, et al
    Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer. 2017 Feb 27. doi: 10.1007/s12282-017-0764.
    PubMed     Text format     Abstract available
    
    
    
91. UOMORI T, Horimoto Y, Mogushi K, Matsuoka J, et al
    Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients.
    Breast Cancer. 2017 Feb 20. doi: 10.1007/s12282-017-0761.
    PubMed     Text format     Abstract available
    
    
    
92. ALTUNDAG K
    Does longer disease-free interval affect the complete remission in metastatic breast cancer?
    Breast Cancer. 2017 Feb 16. doi: 10.1007/s12282-017-0762.
    PubMed     Text format    
    
    
    January 2017
93. KOIKE Y, Ohta Y, Saitoh W, Yamashita T, et al
    Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Breast Cancer. 2017 Jan 31. doi: 10.1007/s12282-017-0757.
    PubMed     Text format     Abstract available
    
    
    
94. LUO M, Ding L, Li Q, Yao H, et al
    miR-668 enhances the radioresistance of human breast cancer cell by targeting IkappaBalpha.
    Breast Cancer. 2017 Jan 30. doi: 10.1007/s12282-017-0756.
    PubMed     Text format     Abstract available
    
    
    
95. INOUE M, Nakagomi H, Nakada H, Furuya K, et al
    Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Breast Cancer. 2017 Jan 20. doi: 10.1007/s12282-017-0753.
    PubMed     Text format     Abstract available
    
    
    
96. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-016-0749.
    PubMed     Text format     Abstract available
    
    
    
97. TANAKA S, Suzuki K, Sakaguchi M
    The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-017-0752.
    PubMed     Text format     Abstract available
    
    
    
98. GALLI G, Tessari A, Porcu L, Bregni G, et al
    Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-017-0751.
    PubMed     Text format     Abstract available
    
    
    
99. HALLAJIAN Z, Mahjoubi F, Nafissi N
    Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-016-0750.
    PubMed     Text format     Abstract available
    
    
    
100. FUTAMURA M, Nagao Y, Ishihara K, Takeuchi M, et al
     Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
     Breast Cancer. 2017 Jan 3. doi: 10.1007/s12282-016-0748.
     PubMed     Text format     Abstract available
     
     
     
101. SUGIE T, Toi M
     Antitumor immunity and advances in cancer immunotherapy.
     Breast Cancer. 2017;24:1-2.
     PubMed     Text format    
     
     
     December 2016
102. PARK JH
     The effects of complex exercise on shoulder range of motion and pain for women with breast cancer-related lymphedema: a single-blind, randomized controlled trial.
     Breast Cancer. 2016 Dec 23. doi: 10.1007/s12282-016-0747.
     PubMed     Text format     Abstract available
     
     
     November 2016
103. VELAEI K, Samadi N, Soltani S, Barazvan B, et al
     NFkappaBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
104. LI T, Liu Y, Xiao H, Xu G, et al
     Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
105. HOSSAIN A, Murshid GM, Zilani MN, Islam F, et al
     TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
106. GUVELI H, Guveli ME, Sen F, Oflaz S, et al
     Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
107. IMAMURA T, Yamamoto-Ibusuki M, Sueta A, Kubo T, et al
     Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
     Breast Cancer. 2016;23:876-885.
     PubMed     Text format     Abstract available
     
     
     
108. YAMASHITA H, Ogiya A, Shien T, Horimoto Y, et al
     Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
     Breast Cancer. 2016;23:830-843.
     PubMed     Text format     Abstract available
     
     
     
109. SHIMO A, Tsugawa K, Tsuchiya S, Yoshie R, et al
     Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution.
     Breast Cancer. 2016;23:851-860.
     PubMed     Text format     Abstract available
     
     
     October 2016
110. MARUTHANILA VL, Elancheran R, Kunnumakkara AB, Kabilan S, et al
     Recent development of targeted approaches for the treatment of breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
111. TANE K, Egawa C, Takao S, Yamagami K, et al
     Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
112. TAN T, Zhang K, Chen W
     Erratum to: Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
     Breast Cancer. 2016.
     PubMed     Text format    
     
     
     
113. YANG J, Tan Q, Fu Q, Zhou Y, et al
     Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     September 2016
114. NAKADA H, Nakagomi H, Hirotsu Y, Amemiya K, et al
     A study of tumor heterogeneity in a case with breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
115. OGIYA A, Yamazaki K, Horii R, Shien T, et al
     Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
116. UEMATSU T
     Possible supplemental breast cancer screening modalities.
     Breast Cancer. 2016.
     PubMed     Text format    
     
     
     August 2016
117. ZHANG X, Fan Y, Liu B, Qi X, et al
     Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
118. IKEDA T, Sugie T, Shimizu A, Toi M, et al
     Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
119. SAKAKIBARA J, Sakakibara M, Shiina N, Fujimori T, et al
     Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
120. IMOTO S, Yamauchi C, Komoike Y, Tsugawa K, et al
     Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
121. HSIEH WC, Lin C, Chen DR, Yu WF, et al
     Genetic polymorphisms in APE1 Asp148Glu(rs3136820) as a modifier of the background levels of abasic sites in human leukocytes derived from breast cancer patients and controls.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
122. LI J, Ren J, Sun W
     Systematic review of ixabepilone for treating metastatic breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     July 2016
123. ANDRYSZAK P, Wilkosc M, Zurawski B, Izdebski P, et al
     Verbal fluency in breast cancer patients treated with chemotherapy.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
124. TAN T, Zhang K, Sun WC
     Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     June 2016
125. NAGATA T, Shimada Y, Sekine S, Moriyama M, et al
     KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
126. EICHLER M, Singer S, Janni W, Harbeck N, et al
     Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
127. UEMATSU T
     The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
128. PORDELI M, Nakhjiri M, Safavi M, Ardestani SK, et al
     Anticancer effects of synthetic hexahydrobenzo [g]chromen-4-one derivatives on human breast cancer cell lines.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     May 2016
129. HONDA K, Takeshita K, Murotani K, Mitsuma A, et al
     Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     
     
130. MORIYA T
     The current topics of surgical pathology of breast cancer in Japan.
     Breast Cancer. 2016.
     PubMed     Text format    
     
     
     
131. KACZYNSKA A, Herman-Antosiewicz A
     Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
     Breast Cancer. 2016.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: